EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review

Caroline Hirsch iD, Nina Kreuzberger iD, Nicole Skoetz iD, Ina Monsef iD, Stefan Kluge iD, Christoph D Spinner iD, Jakob J Malin iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae482 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Caroline Hirsch und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Public Health, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50939 Cologne, Germany. Hauptthemen laut MEDLINE: Antiviral Agents, Immunocompromised Host, COVID-19 Drug Treatment, COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovation Fund of the German Joint Federal Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Persistent COVID-19 (pCOVID-19) in immunocompromised patients is characterized by unspecific symptoms and pulmonary infiltrates due to ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) replication. Treatment options remain unclear, leading to different approaches, including combination therapy and extended durations. The purpose of this study was to assess the efficacy and safety of antiviral therapies for pCOVID-19 in immunocompromised patients since the Omicron surge.

Methods

We searched MEDLINE and Scopus from 1 January 2022 to 6 August 2024 for cohort studies and case series on nirmatrelvir/ritonavir, remdesivir, ensitrelvir and molnupiravir. Evidence certainty was rated using Grading of Recommendations Assessment, Development, and Evaluation for outcomes including viral clearance, recurrence/relapse, mortality, adverse events (AEs) and symptom resolution.

Results

Thirteen studies involving 127 cases were included. Evidence certainty was very low. In combination therapy with at least two direct antiviral agents, viral clearance was 79%, with a 16% recurrence rate. All-cause mortality was 9%, and mortality was 6% while SARS-CoV-2 positive. In 47 cases, AEs were reported in 11%. Symptom resolution ranged from 3 to 6 days in two studies. In combination therapy with one direct antiviral agent and passive immunization, viral clearance was 89%, with an 11% recurrence rate and no deaths. In four documented cases, no AEs were observed. In monotherapy, viral clearance was 100%, with a 15% recurrence rate. One death, unrelated to SARS-CoV-2, occurred. In 12 documented cases, no AEs were observed.

Conclusions

Based on very low certainty evidence, combining one direct antiviral with passive immunization resulted in high rates of viral clearance and few recurrences. AEs occurred in cases treated with at least two direct antivirals. Controlled studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsImmunocompromised HostCOVID-19 Drug TreatmentCOVID-19HumansSARS-CoV-2Treatment OutcomeDrug Therapy, CombinationAlanineImmunization, PassiveAdenosine Monophosphate

Substanzen

Antiviral AgentsremdesivirAlanineAdenosine Monophosphate

Autor:innen und Institutionen

  • Institute of Public Health, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50939 Cologne, Germany.
  • Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinstr. 52, 20246 Hamburg, Germany.
  • Department of Clinical Medicine, Clinical Department for Internal Medicine II, TUM School of Medicine and Health, University Medical Center, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany.
  • Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, University of Cologne, Kerpener Str. 62, 50939 Cologne, Germany.

ORCID-Profile: Caroline Hirsch, Nina Kreuzberger, Nicole Skoetz, Ina Monsef, Stefan Kluge, Christoph D Spinner, Jakob J Malin

Förderung

  • Innovation Fund of the German Joint Federal Committee

Zitieren

APA

Hirsch, C., Kreuzberger, N., Skoetz, N., Monsef, I., Kluge, S., Spinner, C. D., & Malin, J. J. (2025). Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae482

Vancouver

Hirsch C, Kreuzberger N, Skoetz N, Monsef I, Kluge S, Spinner CD, et al. Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae482

BibTeX
@article{Hirsch2025,
  author = {Hirsch, Caroline and Kreuzberger, Nina and Skoetz, Nicole and Monsef, Ina and Kluge, Stefan and Spinner, Christoph D and Malin, Jakob J},
  title = {Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae482}
}
Kostenlos starten →